A look at Neuralink and other brain-computer interface startups, as the number of people with brain implants is set to double from ~100 in the next 12 months
Christopher Mims / Wall Street Journal :
Context & Ripple Effects
Neuralink’s path has moved from early ambitions for a direct cortical interface to a small, paralysis-focused human study: it opened enrollment for its first human trial in 2023. Earlier coverage also framed the field as a broader technical race involving Neuralink and a DARPA array program, not a single-company effort.
The projected increase in implant recipients matters because it would expand the still-small base of real-world users just as Neuralink faces a familiar tension between unusually high visibility and questions about hype relative to rivals.
First-order effects
- A doubling from roughly 100 implanted people would give BCI developers a materially larger pool of patients using devices outside laboratory prototypes, creating more operational and clinical feedback for the companies running those programs.
- Neuralink and peer startups become more directly comparable on their ability to recruit participants, perform implants and support users over time, rather than on technical demonstrations alone.
Second-order effects
- More active implant programs raise the value of reliable surgical workflows, device support and trial operations—areas that can become practical bottlenecks as participant counts rise.
- Rivals may face greater pressure to distinguish their interfaces and evidence base, while Neuralink’s public profile makes its progress especially consequential for expectations around the category.
Third-order effects
- If recipient growth persists, BCI competition could shift from proving that implants can be placed in people to building repeatable systems for implantation, monitoring and long-term support.
- The field may increasingly be judged on durable patient outcomes and scalable clinical execution, tempering the advantage of media attention alone.
The trend: Brain-computer interfaces are entering an early transition from isolated human trials toward a small but expanding installed base of implanted users.